250 related articles for article (PubMed ID: 37436743)
1. Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer.
Patelli G; Mauri G; Tosi F; Amatu A; Bencardino K; Bonazzina E; Pizzutilo EG; Villa F; Calvanese G; Agostara AG; Stabile S; Ghezzi S; Crisafulli G; Di Nicolantonio F; Marsoni S; Bardelli A; Siena S; Sartore-Bianchi A
Clin Cancer Res; 2023 Nov; 29(22):4530-4539. PubMed ID: 37436743
[TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Nakamura Y; Yoshino T
Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
Sartore-Bianchi A; Pietrantonio F; Lonardi S; Mussolin B; Rua F; Crisafulli G; Bartolini A; Fenocchio E; Amatu A; Manca P; Bergamo F; Tosi F; Mauri G; Ambrosini M; Daniel F; Torri V; Vanzulli A; Regge D; Cappello G; Marchiò C; Berrino E; Sapino A; Marsoni S; Siena S; Bardelli A
Nat Med; 2022 Aug; 28(8):1612-1618. PubMed ID: 35915157
[TBL] [Abstract][Full Text] [Related]
4. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review.
Ciardiello D; Mauri G; Sartore-Bianchi A; Siena S; Zampino MG; Fazio N; Cervantes A
Cancer Treat Rev; 2024 Mar; 124():102683. PubMed ID: 38237253
[TBL] [Abstract][Full Text] [Related]
5. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
7. The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review.
Vaghi C; Mauri G; Agostara AG; Patelli G; Pizzutilo EG; Nakamura Y; Yoshino T; Siena S; Sartore-Bianchi A
Cancer Treat Rev; 2023 Jan; 112():102488. PubMed ID: 36410093
[TBL] [Abstract][Full Text] [Related]
8. Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis.
Vlachou MS; Mauri D; Zarkavelis G; Ntellas P; Tagkas C; Gkoura S; Pentheroudakis G
Exp Oncol; 2021 Sep; 43(3):252-256. PubMed ID: 34591420
[TBL] [Abstract][Full Text] [Related]
9. Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis.
Kim S; Cha Y; Lim Y; Roh H; Kang JK; Lee KH; Kim MJ; Park JW; Ryoo SB; Kim HP; Jeong SY; Park KJ; Han SW; Kim TY
Int J Cancer; 2023 Aug; 153(3):571-583. PubMed ID: 37194418
[TBL] [Abstract][Full Text] [Related]
10. Truncal Dynamics May Trump: Serial ctDNA to Predict Early Therapeutic Response.
Eluri M; Kopetz S; Parseghian CM
Clin Cancer Res; 2023 Jan; 29(2):302-304. PubMed ID: 36378102
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.
Topham JT; O'Callaghan CJ; Feilotter H; Kennecke HF; Lee YS; Li W; Banks KC; Quinn K; Renouf DJ; Jonker DJ; Tu D; Chen EX; Loree JM
J Clin Oncol; 2023 Jan; 41(3):485-496. PubMed ID: 36007218
[TBL] [Abstract][Full Text] [Related]
12. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.
Wang F; Huang YS; Wu HX; Wang ZX; Jin Y; Yao YC; Chen YX; Zhao Q; Chen S; He MM; Luo HY; Qiu MZ; Wang DS; Wang FH; Xu M; Li YH; Xu RH
Gut; 2022 Jul; 71(7):1340-1349. PubMed ID: 34489309
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer.
Mauri G; Vitiello PP; Sogari A; Crisafulli G; Sartore-Bianchi A; Marsoni S; Siena S; Bardelli A
Br J Cancer; 2022 Aug; 127(3):394-407. PubMed ID: 35264786
[TBL] [Abstract][Full Text] [Related]
15. CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice.
D'Onofrio R; Caputo F; Prampolini F; Spallanzani A; Gelsomino F; Bettelli S; Manfredini S; Reggiani Bonetti L; Carotenuto P; Bocconi A; Dominici M; Luppi G; Salati M
Tumori; 2023 Aug; 109(4):387-393. PubMed ID: 36113407
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.
Montagut C; Argilés G; Ciardiello F; Poulsen TT; Dienstmann R; Kragh M; Kopetz S; Lindsted T; Ding C; Vidal J; Clausell-Tormos J; Siravegna G; Sánchez-Martín FJ; Koefoed K; Pedersen MW; Grandal MM; Dvorkin M; Wyrwicz L; Rovira A; Cubillo A; Salazar R; Desseigne F; Nadal C; Albanell J; Zagonel V; Siena S; Fumi G; Rospo G; Nadler P; Horak ID; Bardelli A; Tabernero J
JAMA Oncol; 2018 Apr; 4(4):e175245. PubMed ID: 29423521
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer.
Benavides M; Alcaide-Garcia J; Torres E; Gil-Calle S; Sevilla I; Wolman R; Durán G; Álvarez M; Reyna-Fortes C; Ales I; Pereda T; Robles M; Kushnir M; Odegaard J; Faull I; Alba E
ESMO Open; 2022 Jun; 7(3):100481. PubMed ID: 35525184
[TBL] [Abstract][Full Text] [Related]
18. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
[TBL] [Abstract][Full Text] [Related]
19. Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer.
Cao W; Xu Y; Chang L; Gong Y; Li L; Mo X; Zhang X; Lin G; Zhou J; Liu D; Yi Y; Dai P; Zhu C; Liu T; Chu Y; Guan Y; Chen Y; Wang J; Xia X; Yang L; Yi X; Cheng Y
Mol Cancer Ther; 2019 Jun; 18(6):1158-1167. PubMed ID: 31015309
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database.
Nakamura Y; Olsen S; Zhang N; Liao J; Yoshino T
Curr Oncol; 2022 May; 29(5):3433-3448. PubMed ID: 35621667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]